Welcome

We are thrilled to welcome you to Frontiers of Proteomics 2026, an exclusive evening where leading scientists, industry experts, and innovators come together to explore the latest breakthroughs in proteomics. As Evosep marks its 10-year anniversary, this year’s event is both a celebration of the remarkable progress made across the field and an opportunity to look ahead to the next frontier.

The event will be hosted at Evosep headquarters in Odense, Denmark, on December 7, 2026, from 15:00 to 21:00.

Event Details:

Date

December 7, 2026

}

Time

15:00 – 21:00

Venue

Evosep Headquarters

Highlights of the Event

  • Co-Exhibition Opportunity: Industry partners are invited to co-exhibit roll ups, showcasing your latest innovations and solutions in the field of proteomics.
  • Networking: Engage with peers, thought leaders, and customers from the proteomics community in a dynamic environment.
  • Dine and Learn: The event will conclude with a dinner, providing an opportunity for relaxed conversations and deeper connections.

This event is not just a meeting of minds but also a celebration of the leaps we have made in proteomics and a look forward to the future we are building together. Your presence would be invaluable as we discuss, deliberate, and dine.

Program

15:00 – 15:30

Meet and greet

15:30 – 15:45

Welcome & Intro

15:45 – 17:15

Keynote speakers

17:15 – 18:00

Guided tour of our HQ

18:00 – 19:30

Networking and exhibition

19:30 – 21:00

Buffet dinner

Keynote speakers

The Novo Nordisk Foundation logo

Broken Receptors, Failing Fat, Reversible Blockade: Rare Syndromes as a Guide to Metabolic Disease

Talk by Thilo Samson Chillon, Postdoctoral researcher at OUH Odense 

Type 2 diabetes is common and heterogeneous, which makes it difficult to distinguish cause from consequence. In contrast, rare insulin-resistance syndromes isolate specific mechanisms, such as defective insulin receptors, autoantibodies that block them, or failing fat tissue. By profiling the plasma proteome of 117 individuals, we investigated the molecular changes associated with each defect and those that are shared or reversed when the blockade is lifted during remission. Each mechanism has its own protein signature, and a shared extracellular matrix core emerges. During remission, some aspects of the signature normalise, while the extracellular matrix core persists.

The Novo Nordisk Foundation logo

Translating Clinical Proteomics into Practice – from discovery to clinical application

Talk by Annelaura Bach Nielsen, Senior Data Scientist at Copenhagen University Hospital

Mass spectrometry-based proteomics enables large-scale biomarker discovery, yet few candidates reach routine clinical use. Crossing this “valley of death” requires more than promising biomarkers: it demands clear clinical questions, robust and scalable assays, clinically interpretable results, and integration into existing laboratory workflows. At the Department of Clinical Biochemistry, Copenhagen University Hospital – Bispebjerg and Frederiksberg Hospital, we have established a framework that brings together proteomics, bioinformatics, machine learning, and clinical laboratory infrastructure to support this translation. Drawing on ongoing projects and future plans, this talk will explore our approach to connecting discovery-scale proteomics with clinical needs and developing a path towards diagnostic implementation.

 

Register for evosep Frontiers event  

We cannot wait for you to join our evening event.

Pop-up Bot
Chat